medigraphic.com
ISSN 2992-779X (Electronic)
ISSN 2007-6452 (Print)

2016, Number 2

<< Back Next >>

Investigación en Discapacidad 2016; 5 (2)

Values of plasma homocysteine in patients over 65 years in a third level health institution of Mexico City

Serrano-Miranda AT, Jiménez HBL, Hernández ZE, Arenas SML, Zavala HC, Ramírez PE

Language: Spanish
References: 21
Page: 81-87
PDF size: 181.64 Kb.


ABSTRACT

Objective: To determine the levels of homocysteine (Hcy) in older adults and the possible association with the studied variables. Methodology: Cross-sectional, descriptive and exploratory design; both sexes, › 65 years. Sociodemographic and clinical characteristics were evaluated; 5 mL of blood were extracted; classification used for Hcy: Normal 5-14, µmol/L 15-29 slight, ≥ 30 high. Plasma quantitation by HPLC. Patients were grouped according to these determinations. Descriptive statistics, normality testing of Kolmogorov-Smirnov, χ2 categorical variables, unilateral ANOVA, multiple linear regression model: predictive variables (sociodemographic and clinical characteristics), dependent variable (Hcy levels). Significance level of p ‹ 0.05. Results: N = 149, age 76.6 ± 7.2, 65% women, › 85 years, widows 68.2% (p = 0.003). Media Hcy, women 22.3 ± 11.8, men 23.4 ± 11.9; General 22.7. Hcy concentration was different in all age groups; the most frequent level of this metabolite was 15-29 µmol/L with p = 0.001. In one-way ANOVA we found no differences among the three groups, weight (p = 0.001), BMI (p = 0.027), age (p = 0.054) and hypertension (p = 0.040). The predictor variables in the model were age: p = 0.002; BMI p = 0.030; osteoporosis p = 0.001 and fractures p = 0.022; dyslipidemia p = 0.088. In this first study that determines the levels of Hcy and sets the frequency by age in older adults, most of them showed elevated levels of Hcy, suggesting that it is a risk factor for the diseases studied. Is necessary to make future epidemiological studies to establish the possible causal link between Hcy and the presence of certain diseases.


REFERENCES

  1. Córdoba A, Blanco F, González F. Bases moleculares de la hiperhomocisteinemia. Quim Clin. 1998; 17 (1): 5-18.

  2. Bjørke MA, Ueland PM. Homocysteine and methylmalonic in diagnosis and risk assessment from infancy to adolescent. Am J Clin Nutr. 2003; 78 (1): 7-21.

  3. Kian T, Zavaleta M, Romero B. Valores referenciales de homocisteína plasmática en adultos aparentemente sanos de Lima-Perú. Diagnóstico (Internet). 2002 citado 14 Abril 2002; 41 (1). Disponible en: http://www.fihu-diagnostico. org.pe/revista/numeros/2002/enefeb02/28-36

  4. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985; 37 (1): 1-31.

  5. Moghadasian MH, McManus BM, Frohlich JJ. Homocystine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med. 1997; 157 (20): 2299-2308.

  6. Rivara ML, Di Genaro G, González RD. Homocisteína y enfermedad vascular oclusiva. Revista de Posgrado de la VIa Cátedra de Medicina. 2006; 154: 24-30.

  7. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998; 49: 31-62.

  8. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996; 27 (3): 517-527.

  9. Córdoba A, Blanco F, González F. Hiperhomocisteinemia, un nuevo marcador de riesgo vascular. Med Clin (Barc). 1997; 109: 715-725.

  10. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993; 270 (22): 2693-2698.

  11. Vangelder E, Delecourt F, Cardozo MB, Dhondt JL, Forzy G. Hyperhomocysteinaemia and type 2 diabetes. Ann Biol Clin (Paris). 2006; 64 (5): 485-489.

  12. Setola E, Monti LD, Galluccio E, Palloshi A, Fragasso G, Paroni R et al. Insulin resistance and endotelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol. 2004; 151 (4): 483-489.

  13. Religa D, Czyzewski K, Styczynska M, Peplonska B, Lokk J, Chodakowska ZM et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson’s disease. Neurosci Lett. 2006; 404 (1-2): 56-60.

  14. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006; 354 (26): 2764-2772.

  15. Malinow MR, Kang SS, Taylor LM, Wong PW, Coull B. Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation. 1989; 79 (6): 1180-1188.

  16. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med. 1994; 236 (6): 633-641.

  17. Vrentzos GE, Papadakis JA, Vardakis KE, Maliaraki N, Stilianou K. Intravenous administration of vitamin B12 in the treatment of hyperhomocysteinemia associated with end-stage renal disease. J Nephrol. 2003; 16 (4): 535-539.

  18. Seshadri N, Robinson K. Homocisteína, vitaminas B, y arteriopatía coronaria. Medical Clinics of North America. 2000; 84: 219-241.

  19. Martin SC, Tsakas-Ampatzis I, Bartlett WA, Jones AF. Measurement of plasma total homocysteine by HPLC with coulometric detection. Clin Chem. 1999; 45 (1): 150-152.

  20. Diario Oficial de la Federación. Manejo integral de la Obesidad. Norma Oficial Mexicana NOM-174-SSA1-1998: 3-4.

  21. Bray G, Bouchard C, James WPT. Definitions and proponed current classifications of obesity Handbook of obesity, Vol. 2, 4th ed. New York: Marcel Dekker, 1998. pp. 53-75.




2020     |     www.medigraphic.com